Sarepta Therapeutics, a biotechnology company specializing in gene-silencing technology, has reported encouraging results from two clinical trials for the treatment of facioscapulohumeral muscular dystrophy type 1 (FSHD1) and myotonic dystrophy type 1 (DM1). These drugs, developed using the company’s siRNA platform, interrupt the process by which proteins are made, reducing or knocking down the target protein or mRNA.

The studies showed that a single dose of SRP-1001 in FSHD1 and SRP-1003 in DM1 resulted in a significant reduction of the target protein or mRNA, with the majority of adverse events being mild to moderate and not dose dependent. This is significant because both FSHD1 and DM1 are caused by an excess of mutant proteins or toxic messenger RNA (mRNA).

Sarepta’s use of siRNA technology holds great promise for the treatment of muscular dystrophy, as it has the potential to silence specific disease-causing genes. The company’s stock jumped over 22% in morning trades, surpassing both its 50-day and 200-day moving averages.

Muscular dystrophy is a group of genetic disorders that affect muscle strength and function. FSHD1 and DM1 are two of the most common forms of muscular dystrophy, each affecting different parts of the body. Existing treatments for these conditions focus on managing symptoms rather than addressing the underlying genetic cause.

Sarepta’s gene-silencing technology has shown potential in treating other diseases as well, including Huntington’s disease and spinal muscular atrophy. The company is continuing to explore the use of siRNA in various therapeutic areas, including oncology and rare genetic disorders.